Loading data for TECH — first visit, this takes a few seconds.

アラート

Bio-Techne Corporation (TECH)

NasdaqGS: TECH · リアルタイム株価 · USD

72.46

+0.24 (0.33%)

終値時点： Aug 18, 2026, 3:59 PM

0.33% (1D)

買気配	66.68
時価総額	11.3B
売上高（TTM）	1.22B
純利益（TTM）	181.86M
ベータ	1.28
EPS（TTM）	1.16
PER（TTM）	62.5
予想PER	31.29
PBR（TTM）	5.44
PSR（TTM）	9.30
Earnings Date	Nov 9, 2026

売気配	78.27
出来高	1,664,301
平均出来高（20日）	4,828,153
始値	72.39
前日終値	72.22
当日レンジ	72.38 - 72.56
52週レンジ	43.20 - 72.62
アナリスト	n/a
目標株価	n/a
配当	$0.32 (0.44%)
権利落ち日	2026年8月24日

TECHについて

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cel...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Feb 9, 1989

従業員数 3,000

上場取引所 NasdaqGS

ティッカー TECH

ウェブサイト https://www.bio-techne.com

企業情報の全文

業績

2025年のBio-Techneの売上高は1.22Bで、前年の1.16Bから5.23%の増加でした。利益は73.4Mで、-56.34%の減少でした。

財務諸表

決算サプライズ

Bio-TechneはAug 12, 2026に四半期決算を発表しました：

売上高は $311.42M で、予想を下回りました $0, うち -1.51% の前年比減少.

EPSは 0.52 で、予想を下回りました 0.00, うち -1.89% の前年比減少.

次回決算発表

Bio-Techne Corporationの決算発表予定日は Nov 9, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

1日前 · Barchart

Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.

1日前 · StockStory

3 High-Flying Stocks We Approach with Caution

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

6日前 · Zacks

TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

1週間前 · StockStory

Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 pe...

1週間前 · Simply Wall St.

Is Bio-Techne (TECH) Above Fair Value After A 44% Return?

Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at ...

2ページ中1ページ

Bio-Techne Corporation (TECH)